ABSTRACT
Objective:
This study aimed to assess the relationship between sodium-glucose cotransporter-2 inhibitors and arrhythmias in individuals with type 2 diabetes mellitus who had a preserved ejection fraction.
Material and Methods:
The study comprised 70 random individuals who were admitted the University of Health Sciences Turkey, Antalya Training and Research Hospital internal medicine policlinic between October 2019 and May 2021 and who started empaglifozin. The patients’ electrocardiograms were obtained at the start and finish of the sixth month. At the start and after 6 months of empaglifozin treatment, echocardiography was done.
Results:
When basal and 6th month electrocardiograms were compared, significant changes were observed in P wave dispersion (0.0376±0.005- 0.0361±0.0049 p<0.007), QT interval dispersion (0.0389±0.0052-0.0376±0.0043 p<0.005) and QTc interval dispersion (0.051±0.0047- 0.049±0.0047 p<0.003).
Conclusions:
In our study, we concluded that empaglifozin has a direct and indirect beneficial effect on arrhythmia and does not have a harmful effect. Longer follow-up research will be guided by the results of our study.
Keywords: Sodium-glucose cotransporter 2 inhibitors (SGLT2is), type 2 diabetes mellitus, P wave dispersion, QT dispersion
References
1
Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab 2019;21(2):210-217.
2
Lynge TH, Svane J, Pedersen-Bjergaard U, Gislason G, Torp-Pedersen C, Banner J, et al. Sudden cardiac death among persons with diabetes aged 1-49 years: a 10-year nationwide study of 14 294 deaths in Denmark. Eur Heart J 2020;41(28):2699-2706.
3
Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. J Am Coll Cardiol 2019;74(8):1107-1115.
4
Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009;119(18):2516-2525.
5
Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, et al. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol 2019;74(17):2204-2215.
6
Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol 2020;19(1):9.
7
Grisanti LA. Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes. Front Physiol 2018;9:1669.
8
Zelniker TA, Braunwald E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol 2018;72(15):1845-1855.
9
Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, et al. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2020;9(3):e014908.
10
Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol 2019;18(1):112.
11
Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014;8(4):262-275.
12
Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 2020;141(15):1227-1234.
13
Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail 2020;22(1):126-135.
14
Chen HY, Huang JY, Siao WZ, Jong GP. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol 2020;19(1):73.
15
Bonora BM, Raschi E, Avogaro A, Fadini GP. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovasc Diabetol 2021;20(1):39.
16
Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVDREAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab 2018;20(2):344-351.
17
Tükek T, Akkaya V, Demirel S, Sözen AB, Kudat H, Atilgan D, et al. Effect of Valsalva maneuver on surface electrocardiographic P-wave dispersion in paroxysmal atrial fibrillation. Am J Cardiol 2000;85(7):896-899.
18
Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000;36(6):1749-1766.
19
Andrikopoulos GK, Dilaveris PE, Richter DJ, Gialafos EJ, Synetos AG, Gialafos JE. Increased variance of P wave duration on the electrocardiogram distinguishes patients with idiopathic paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2000;23(7):1127-1132.
20
Kawano S, Hiraoka M, Sawanobori T. Electrocardiographic features of P waves from patients with transient atrial fibrillation. Jpn Heart J 1988;29(1):57-67.
21
Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998;135(5 Pt 1):733-738.
22
Garson A Jr. How to measure the QT interval--what is normal? Am J Cardiol 1993;72(6):14B-16B.
23
Cherney DZ, Odutayo A, Aronson R, Ezekowitz J, Parker JD. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week. J Am Coll Cardiol 2019;74(20):2511-2524.
24
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373(22):2117-2128.
25
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381(21):1995-2008.
26
Siscovick DS, Sotoodehnia N, Rea TD, Raghunathan TE, Jouven X, Lemaitre RN. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord 2010;11(1):53-59.
27
Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol 2010;47 Suppl 1(Suppl 1):161-168.
28
Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015;36(27):1718-1727.
29
Özgür Barış V, Dinçsoy B, Gedikli E, Erdemb A. Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats. Kardiol Pol 2021;79(1):53-57.
30
Azam MA, Chakraborty P, Si D, Du B, Massé S, Lai PFH, et al. Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. Life Sci 2021;276:119440.
31
İnci Ü, Güzel T. The effect of empagliflozin on index of cardio-electrophysiological balance in patients with diabetes mellitus. Pacing Clin Electrophysiol 2023;46(1):44-49.
